Meeting
2023 ASCO Annual Meeting
NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).
Authors
David B. Page
Providence Cancer Institute, Portland, OR
David B. Page , Alan Su , Nicole Moxon , Staci L. Mellinger , Tracy Kelly , Alison Katherine Conlin , Zheng Zhu Topp , Pippa Newell , Nicole Fredrich , Kristen P. Massimino , Yaping Wu , William L Redmond , Shaghayegh Aliabadi , Zhaoyu Sun , James Imatani , Sasha E. Stanton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04373031
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 604)
DOI
10.1200/JCO.2023.41.16_suppl.604
Abstract #
604
Poster Bd #
434
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
First Author: Christine H. Chung
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra
Poster
2021 ASCO Annual Meeting
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
First Author: Ignacio Ortego